World's Best Scientists 2026 revealed!
Carlo Gambacorti-Passerini

Carlo Gambacorti-Passerini

D-Index & Metrics

Medicine

D-Index
87
Citations
41834
World Ranking
13413
National Ranking
513

Carlo Gambacorti-Passerini publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Carlo Gambacorti-Passerini sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 531 publications — 63rd percentile

63% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Carlo Gambacorti-Passerini D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Carlo Gambacorti-Passerini sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 87 D-Index — 34th percentile

34% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Carlo Gambacorti-Passerini is affiliated with the University of Milano-Bicocca in Italy, focusing primarily on the field of medicine with a specialization in hematology.

The scientist's research contributions span several interconnected subfields, including hematology, genetics, public health, oncology, and molecular biology. This interdisciplinary approach is reflected in the topics they have extensively investigated:

  • Chronic Myeloid Leukemia Treatments
  • Chronic Lymphocytic Leukemia Research
  • Acute Lymphoblastic Leukemia Research
  • Lymphoma Diagnosis and Treatment
  • Eosinophilic Disorders and Syndromes
  • Acute Myeloid Leukemia Research
  • Myeloproliferative Neoplasms: Diagnosis and Treatment

Their recent publications include a range of studies published between 2020 and 2022, appearing in peer-reviewed journals with significant scientific reputations. Selected papers are as follows:

  • "Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study" (2020), The Lancet Haematology
  • "Integrative pathway enrichment analysis of multivariate omics data" (2020), Nature Communications
  • "Cancer LncRNA Census reveals evidence for deep functional conservation of long noncoding RNAs in tumorigenesis" (2020), Communications Biology
  • "Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial" (2022), Leukemia
  • "Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy" (2022), Blood

Frequent co-authors of this researcher, indicating active collaboration within the scientific community, include:

  • Rocco Piazza
  • Luca Mologni
  • Andrea Aroldi
  • Tim H. Brümmendorf
  • Pau Montesinos

The scientist has published regularly in specific venues, highlighting established channels for their research dissemination. The most common publication venues are:

  • Blood
  • HemaSphere
  • Clinical Lymphoma Myeloma & Leukemia
  • Journal of Clinical Oncology
  • Nature Communications

Best Publications

  • Pan-cancer analysis of whole genomes

    Peter J. Campbell;Gad Getz;Jan O. Korbel;Joshua M. Stuart

  • Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

    Hagop M Kantarjian;Charles Sawyers;Andreas Hochhaus;Francois Guilhot

  • Clinical and biological implications of driver mutations in myelodysplastic syndromes.

    Elli Papaemmanuil;Moritz Gerstung;Luca Malcovati;Sudhir Tauro

  • Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study

    Charles L. Sawyers;Andreas Hochhaus;Eric Feldman;John M. Goldman

  • Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.

    Moshe Talpaz;Richard T. Silver;Brian J. Druker;John M. Goldman

  • Somatic SF3B1 Mutation in Myelodysplasia with Ring Sideroblasts

    E. Papaemmanuil;M. Cazzola;J. Boultwood;L. Malcovati

  • A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

    Jorge E. Cortes;D. W. Kim;J. Pinilla-Ibarz;P. Le Coutre

  • Patterns of somatic structural variation in human cancer genomes

    Yilong Li;Nicola D Roberts;Jeremiah A Wala;Jeremiah A Wala;Ofer Shapira;Ofer Shapira

  • The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

    Camille Abboud;Ellin Berman;Adam Cohen

  • Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification.

    Philipp le Coutre;Elena Tassi;Marileila Varella-Garcia;Rossella Barni

  • Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells

    Valentina Zuco;Rosanna Supino;Sabina C Righetti;Loredana Cleris

  • Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial

    Jorge E. Cortes;Dong Wook Kim;Hagop M. Kantarjian;Tim H. Brümmendorf;Tim H. Brümmendorf

  • Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants

    Sara Redaelli;Rocco Piazza;Roberta Rostagno;Vera Magistroni

  • Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias

    Carlo B Gambacorti-Passerini;Rosalind H Gunby;Rocco Piazza;Annamaria Galietta

  • Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

    Jorge E. Cortes;Hagop M. Kantarjian;Tim H. Brümmendorf;Dong Wook Kim

  • Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

    Carlo Gambacorti-Passerini;Laura Antolini;Franois Xavier Mahon;Francois Guilhot

  • Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial

    Jorge E. Cortes;Dong Wook Kim;Javier Pinilla-Ibarz;Philipp D. le Coutre

  • In Vivo Eradication of Human BCR/ABL-Positive Leukemia Cells With an ABL Kinase Inhibitor

    Philipp le Coutre;Luca Mologni;Loredana Cleris;Edoardo Marchesi

  • Role of α1 Acid Glycoprotein in the In Vivo Resistance of Human BCR-ABL+ Leukemic Cells to the Abl Inhibitor STI571

    Carlo Gambacorti-Passerini;Rossella Barni;Philipp le Coutre;Massimo Zucchetti

  • Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial

    Jorge E. Cortes;Carlo Gambacorti-Passerini;M. W. Deininger;Michael J. Mauro

Frequent Co-Authors

Jorge E. Cortes
Jorge E. Cortes Augusta University
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Tim H. Brümmendorf
Tim H. Brümmendorf RWTH Aachen University
Michael W. Deininger
Michael W. Deininger University of Utah
Andreas Hochhaus
Andreas Hochhaus Friedrich Schiller University Jena
Michele Baccarani
Michele Baccarani University of Bologna
Jane F. Apperley
Jane F. Apperley Imperial College London
Francois Guilhot
Francois Guilhot Grenoble Alpes University
Moshe Talpaz
Moshe Talpaz University of Michigan–Ann Arbor
Leonardo Scapozza
Leonardo Scapozza University of Geneva

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

In addition to traditional medical degrees, students are increasingly exploring alternative healthcare career pathways through flexible online programs. With the healthcare industry rapidly evolving, online degrees can open doors to a variety of high-demand fields without the need to attend campus full-time.

For those interested in pharmaceuticals, online pharmacy schools offer accredited programs leading to rewarding pharmacy careers. Similarly, managing medical data is a critical role, and many students pursue their education through online schools for health information management to work in record keeping, compliance, and data analysis.

The demand for skilled billing professionals is also on the rise. Affordably priced medical billing and coding online courses cost significantly less than traditional education, making this a popular choice for career changers and those seeking quick entry into the workforce.

Additionally, those looking to advance their nursing careers can find flexible options through the cheapest online fnp programs, positioning themselves for roles as family nurse practitioners (FNPs) in primary care settings.

Best Scientists Citing Carlo Gambacorti-Passerini

Trending Scientists

Recently Published Articles